Dartsch R C, Fink L, Breithecker A, Markart P, Tello S, Seeger W, Günther A
Abteilung für Innere Medizin, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
Universities of Giessen and Marburg Lung Center (UGMLC), Deutsches Zentrum für Lungenforschung (DZL), Justus-Liebig-Universität Gießen, Klinikstr. 36, 35392, Gießen, Deutschland.
Internist (Berl). 2019 Apr;60(4):345-361. doi: 10.1007/s00108-019-0571-1.
Fibrosing lung diseases describe a heterogeneous group of interstitial lung diseases (ILD) of highly variable etiology, but with a unifying terminal process of irreversible, fibroproliterative destruction of the alveolar surface, loss of compliance and progressive impairment of gas exchange. In view of the heterogeneity, the disastrous prognoses in some cases and the treatment consequences, a thorough differential diagnosis is essential in all patients. Antifibrotic therapies are currently only indicated in idiopathic pulmonary fibrosis (IPF). The only curative therapeutic option is lung transplantation. Therefore, suitable patients should be promptly evaluated.
纤维化性肺病描述了一组病因高度可变的间质性肺病(ILD),但具有一个统一的终末期过程,即肺泡表面发生不可逆的纤维增生性破坏、顺应性丧失和气体交换进行性受损。鉴于其异质性、某些病例的灾难性预后以及治疗后果,对所有患者进行全面的鉴别诊断至关重要。目前抗纤维化疗法仅适用于特发性肺纤维化(IPF)。唯一的治愈性治疗选择是肺移植。因此,应及时评估合适的患者。